Virax Biolabs Group Limited (VRAX) Debt by Year
Virax Biolabs Group Limited carried $305K in long-term debt against $4.2M in cash and equivalents at the end of fiscal year 2026. This represents an increase of 4.5% from the prior fiscal year. The table below carries 6 fiscal years, from 2021 to 2026, and the quarters Virax Biolabs Group Limited has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
VRAX Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
VRAX Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Virax Biolabs Group Limited financials
Frequently Asked Questions
What was Virax Biolabs Group Limited's long-term debt in fiscal year 2026?
Virax Biolabs Group Limited carried $305K in long-term debt against $4.2M in cash and equivalents at the end of fiscal year 2026.
How fast is Virax Biolabs Group Limited's long-term debt growing?
Virax Biolabs Group Limited (VRAX) long-term debt rose by 4.5% year over year, from $292K to $305K in fiscal year 2026.
What was Virax Biolabs Group Limited's long-term debt in the most recent quarter?
Virax Biolabs Group Limited (VRAX) reported $292K in long-term debt in Q3 2025. This represents an increase of 65.3% from the same quarter a year earlier.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Virax Biolabs Group Limited (VRAX) reported on that line in every period on record.